In addition, the palmitoylation of epithelial cell adhesion molecule (EpCAM) affects the formation of a complex among EpCAM, claudin isoforms, and KAI1/CD82, which is important in ovarian cancer progression, whereas 2‐BP treatment inhibits EpCAMP‐CLDN‐KAI1/CD82 complex formation [91]. Here, CD82 is linked to ovarian cancer.